Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota
Journal of Pharmacy and Pharmacology · 02.06.2026 · 78 (6)
DOI: 10.1093/jpp/rgag039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 03.06.2026. Verfasst von Huizi Shangguan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1 Middle Section of Century Avenue, Xianyang 712046, People's Republic of Chi…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Proto-Oncogene Proteins c-akt, Coronary Disease, Gastrointestinal Microbiome. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Xianyang City major scientific and technological innovations special project, Science and Technology Innovative Talent Program of Shaanxi University of Chinese Medicine, Xianyang Innovation Capability Support Plan-Science and Technology Innovation Talents and Excellent Teams-'Scientists+Engineers' Team Construction.
Abstract (Originalsprache)
Objective
To investigate the therapeutic mechanism of Mai Guan Fu Kang Capsule (MGFKC) against coronary heart disease (CHD).
Methods
MGFKC constituents were identified by liquid chromatography–mass spectrometry (LC–MS). Network pharmacology predicted bioactive compounds, targets, and CHD-associated targets. Protein–protein interaction networks were constructed, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. A CHD animal model was used to assess myocardial histopathology, serum biomarkers, inflammatory cytokines, oxidative stress, PI3K/Akt signaling pathway protein expression, gut microbiota, and short-chain fatty acids (SCFAs) metabolism. Key findings Key active components included salvianolic acid B and luteolin. Network analysis indicated involvement of the PI3K/Akt signaling pathway. MGFKC alleviated myocardial injury and histopathological changes, suppressed inflammation and oxidative stress, and regulated PI3K/Akt protein expression. It also ameliorated gut microbiota dysbiosis and restored SCFAs metabolism.
Conclusion
MGFKC exerts multi-target effects against CHD through synergistic regulation of the PI3K/Akt pathway, providing anti-inflammatory, antioxidant, and anti-apoptotic activities. Improvement of gut microbiota and SCFAs metabolism further contributes to its cardioprotective mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1 Middle Section of Century Avenue, Xianyang 712046, People's Republic of China.
- Shaanxi Dongtai Pharmaceutical Company, Qindu District, Xianyang 712000, Shaanxi, People's Republic of China.
ORCID-Profile: Huizi Shangguan
Förderung
- Xianyang City major scientific and technological innovations special project
- Science and Technology Innovative Talent Program of Shaanxi University of Chinese Medicine
- Xianyang Innovation Capability Support Plan-Science and Technology Innovation Talents and Excellent Teams-'Scientists+Engineers' Team Construction
- Shaanxi Provincial Department of Education Youth Innovation Team Scientific Research Plan Project
- Youth Innovation Team of Shaanxi Provincial Department of Education
- Xianyang Innovation Capability Support Plan—Science and Technology Innovation Talents and Excellent Teams—‘Scientists+Engineers’ Team Construction
Zitieren
APA
Shangguan, H., Sun, Z., Wang, X., Ding, L., Bai, F., Sun, Y., Yang, D., Shi, H., Liu, J., & Xie, Y. (2026). Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota. Journal of Pharmacy and Pharmacology, 78(6). https://doi.org/10.1093/jpp/rgag039
Vancouver
Shangguan H, Sun Z, Wang X, Ding L, Bai F, Sun Y, et al. Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota. Journal of Pharmacy and Pharmacology. 2026;78(6). doi:10.1093/jpp/rgag039
BibTeX
@article{Shangguan2026,
author = {Shangguan, Huizi and Sun, Zexuan and Wang, Xin and Ding, Ling and Bai, Fengyun and Sun, Ying and Yang, Dongli and Shi, Huanxian and Liu, Jiping and Xie, Yundong},
title = {Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {6},
doi = {10.1093/jpp/rgag039}
}
EUVIMED